# Non-endoscopic screening for Barrett's oesophagus and early adenocarcinoma

Source: https://onco.cc/ideas/idea-non-endoscopic-barretts-screening/  
OnCo record `idea-non-endoscopic-barretts-screening` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A swallowed sponge on a string can sample the oesophagus in a GP's office. Screen people with chronic reflux to catch adenocarcinoma at a curable stage.

## Summary

The proposal is to screen adults with chronic reflux or long-term acid suppression for Barrett's oesophagus and early adenocarcinoma with a swallowed capsule sponge that can be given in a GP's office rather than by endoscopy. Oesophageal adenocarcinoma has a known precursor, a defined at-risk population and curative endoscopic resection for early disease; the missing piece has been an accessible test. In BEST3, reported in the Lancet in 2020, the Cytosponge-TFF3 test detected many more cases of Barrett's than usual care, and the NIHR-funded BEST4 trial now tests whether screening reduces deaths and shifts diagnosis to stage I. Being tested at scale, with EsoGuard methylation markers and AI histology as possible add-ons, it addresses the bottleneck that the hardest cancers are found late.

## Fields

- Kind: Idea
- Last checked: 2026-09-07
- Hypothesis: Offering capsule-sponge screening to adults on long-term acid suppression increases the proportion of oesophageal adenocarcinomas diagnosed at stage I and reduces oesophageal cancer mortality.
- Rationale: Adenocarcinoma has a known precursor, a defined at-risk population, and curative endoscopic treatment for early disease; the missing piece is an accessible test.
- Proposed test: The BEST4 screening and surveillance arms (mortality and stage-shift endpoints) report in the late 2020s.
- Maturity: being-tested-at-scale

## Sources

- BEST3: Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus (Lancet 2020): https://doi.org/10.1016/S0140-6736(20)31099-0

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- technologies: [DNA methylation profiling](https://onco.cc/technologies/methylation-profiling/), [Endoscopic resection (EMR / ESD)](https://onco.cc/technologies/endoscopic-resection/), [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/)
- terms: [Barrett's oesophagus](https://onco.cc/terms/barretts-esophagus/), [Stage shift](https://onco.cc/terms/stage-shift/)
- key papers: [Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial](https://onco.cc/key-papers/paper-fitzgerald-lancet/)
- bottlenecks: [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/)

---
JSON: https://onco.cc/api/v1/entities/idea-non-endoscopic-barretts-screening.json